These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25101565)

  • 1. Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy.
    Tazzari M; Negri T; Rini F; Vergani B; Huber V; Villa A; Dagrada P; Colombo C; Fiore M; Gronchi A; Stacchiotti S; Casali PG; Pilotti S; Rivoltini L; Castelli C
    Br J Cancer; 2014 Sep; 111(7):1350-62. PubMed ID: 25101565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib malate in solitary fibrous tumor (SFT).
    Stacchiotti S; Negri T; Libertini M; Palassini E; Marrari A; De Troia B; Gronchi A; Dei Tos AP; Morosi C; Messina A; Pilotti S; Casali PG
    Ann Oncol; 2012 Dec; 23(12):3171-3179. PubMed ID: 22711763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumours.
    Spagnuolo RD; Brich S; Bozzi F; Conca E; Castelli C; Tazzari M; Maestro R; Brenca M; Gualeni AV; Gloghini A; Stacchiotti S; Pierotti MA; Pilotti S; Negri T
    Oncotarget; 2016 Jul; 7(29):45015-45026. PubMed ID: 27304187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.
    Stacchiotti S; Negri T; Palassini E; Conca E; Gronchi A; Morosi C; Messina A; Pastorino U; Pierotti MA; Casali PG; Pilotti S
    Mol Cancer Ther; 2010 May; 9(5):1286-97. PubMed ID: 20457621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
    Stacchiotti S; Tortoreto M; Baldi GG; Grignani G; Toss A; Badalamenti G; Cominetti D; Morosi C; Dei Tos AP; Festinese F; Fumagalli E; Provenzano S; Gronchi A; Pennacchioli E; Negri T; Dagrada GP; Spagnuolo RD; Pilotti S; Casali PG; Zaffaroni N
    Eur J Cancer; 2014 Nov; 50(17):3021-8. PubMed ID: 25269954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
    Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
    Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma.
    Mizuno R; Kimura G; Fukasawa S; Ueda T; Kondo T; Hara H; Shoji S; Kanao K; Nakazawa H; Tanabe K; Horie S; Oya M;
    Cancer Sci; 2017 Sep; 108(9):1858-1863. PubMed ID: 28699300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes.
    Raychaudhuri B; Rayman P; Huang P; Grabowski M; Hambardzumyan D; Finke JH; Vogelbaum MA
    J Neurooncol; 2015 Apr; 122(2):293-301. PubMed ID: 25579983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study.
    Stacchiotti S; Simeone N; Lo Vullo S; Morosi C; Greco FG; Gronchi A; Barisella M; Collini P; Zaffaroni N; Dagrada GP; Frezza AM; Mariani L; Casali PG
    Eur J Cancer; 2019 Jan; 106():225-233. PubMed ID: 30528807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.
    Cohen PA; Ko JS; Storkus WJ; Spencer CD; Bradley JM; Gorman JE; McCurry DB; Zorro-Manrique S; Dominguez AL; Pathangey LB; Rayman PA; Rini BI; Gendler SJ; Finke JH
    Immunol Invest; 2012; 41(6-7):680-710. PubMed ID: 23017141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
    Domont J; Massard C; Lassau N; Armand JP; Le Cesne A; Soria JC
    Invest New Drugs; 2010 Apr; 28(2):199-202. PubMed ID: 19352594
    [No Abstract]   [Full Text] [Related]  

  • 12. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.
    Ozao-Choy J; Ma G; Kao J; Wang GX; Meseck M; Sung M; Schwartz M; Divino CM; Pan PY; Chen SH
    Cancer Res; 2009 Mar; 69(6):2514-22. PubMed ID: 19276342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics.
    Finke JH; Rayman PA; Ko JS; Bradley JM; Gendler SJ; Cohen PA
    Cancer J; 2013; 19(4):353-64. PubMed ID: 23867518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Circulating Myeloid Suppressor Cells and Their Role in Tumour Immunology].
    Pilatova K; Budinská E; Bensciková B; Nenutil R; Šefr R; Fedorová L; Hanáková B; Brychtová V; Zdražilová Dubská L
    Klin Onkol; 2017; 30(Supplementum1):166-169. PubMed ID: 28471197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of anti-angiogenic drugs on regulatory T cells in the tumor microenvironment.
    Hu C; Jiang X
    Biomed Pharmacother; 2017 Apr; 88():134-137. PubMed ID: 28103506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.
    Ko JS; Zea AH; Rini BI; Ireland JL; Elson P; Cohen P; Golshayan A; Rayman PA; Wood L; Garcia J; Dreicer R; Bukowski R; Finke JH
    Clin Cancer Res; 2009 Mar; 15(6):2148-57. PubMed ID: 19276286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.
    Chen HM; Ma G; Gildener-Leapman N; Eisenstein S; Coakley BA; Ozao J; Mandeli J; Divino C; Schwartz M; Sung M; Ferris R; Kao J; Wang LH; Pan PY; Ko EC; Chen SH
    Clin Cancer Res; 2015 Sep; 21(18):4073-4085. PubMed ID: 25922428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib.
    DePrimo SE; Bello C
    Ann Oncol; 2007 Sep; 18 Suppl 10():x11-9. PubMed ID: 17761718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
    Diaz-Montero CM; Mao FJ; Barnard J; Parker Y; Zamanian-Daryoush M; Pink JJ; Finke JH; Rini BI; Lindner DJ
    Br J Cancer; 2016 Oct; 115(8):920-928. PubMed ID: 27560553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells.
    Schilling B; Sucker A; Griewank K; Zhao F; Weide B; Görgens A; Giebel B; Schadendorf D; Paschen A
    Int J Cancer; 2013 Oct; 133(7):1653-63. PubMed ID: 23526263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.